Dr. Ye Fu, Ph.D. has played a pivotal role in the development of Stellaromics’ Pyxa, a first-in-class platform for 3D spatial multi-omic profiling. His early contributions in assay chemistry, imaging workflows, and platform design helped establish the scientific foundation for a technology that is redefining how researchers study cellular interaction and function in intact tissues.
Dr. Fu earned his Ph.D. in Chemistry from the University of Chicago under Professor Chuan He, where his pioneering work on reversible RNA modifications helped launch an entirely new field of study. His research, published in leading journals including Cell and Nature Chemical Biology, has garnered more than 18,000 citations. These discoveries contributed to the scientific foundation for the 2023 Wolf Prize in Chemistry, and Dr. Fu remains widely recognized as a pioneer in chemical biology and spatial transcriptomics.
Beyond Stellaromics, Dr. Fu’s career reflects a rare blend of academic excellence, platform innovation, and entrepreneurial impact. As Principal at Plaisance Capital Management, he played a key role in incubating biotech startups such as Aferna Bio, Sedec Therapeutics, and ProteoValent Therapeutics. He continues to serve as a trusted advisor to early-stage ventures, bringing both scientific depth and strategic insights to emerging therapeutic platforms.
With multiple patents, high-impact publications, and a proven track record of new technology innovation, Dr. Fu has established himself as a scientific leader in the fields of molecular biology and genomics technology.